CT imaging findings in patients with advanced hepatocellular carcinoma treated with sorafenib: Alternative response criteria (Choi, European Association for the Study of the Liver, and modified Response Evaluation Criteria in Solid Tumor (mRECIST)) versus RECIST 1.1
Highlights • Response or non-response as defined by the Choi criteria exhibited the highest predictive value for overall survival compared with the EASL, RECIST 1.1 and mRECIST criteria. • Patients with progression at the first follow-up examination are never downstaged. • Neither tumor necrosis nor...
Gespeichert in:
| Veröffentlicht in: | European journal of radiology 2016-01, Vol.85 (1), p.103-112 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 112 |
|---|---|
| container_issue | 1 |
| container_start_page | 103 |
| container_title | European journal of radiology |
| container_volume | 85 |
| creator | Gavanier, M Ayav, A Sellal, C Orry, X Claudon, M Bronowicki, J.P Laurent, V |
| description | Highlights • Response or non-response as defined by the Choi criteria exhibited the highest predictive value for overall survival compared with the EASL, RECIST 1.1 and mRECIST criteria. • Patients with progression at the first follow-up examination are never downstaged. • Neither tumor necrosis nor tumor hypervascularization were independent predictors of tumor response. |
| doi_str_mv | 10.1016/j.ejrad.2015.10.024 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_01659110v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0720048X15301443</els_id><sourcerecordid>1753230879</sourcerecordid><originalsourceid>FETCH-LOGICAL-c448t-cdbf6ff7bff0fd7302de16561e570d60edd7fefc4113301d8cb6b9715369b7b73</originalsourceid><addsrcrecordid>eNqFkl2LEzEUhkdR3O7qLxAkly1sazJfaQWFUqq7UBC2FbwLmeRkmzqT1GSm0n_vmXa7F954FXLmOe8hZ54kec_ohFFWftxNYBeknqSUFViZ0DR_mQzYlKdjzlP-KhlQntIxzac_r5LrGHeU0iKfpW-Sq7TkaV4W-eDF9WJDbCMfrXskxjqNZyTWkb1sLbg2kj-23RKpD9Ip0GQL-MErqOuuloEoGZR1vpGkDSBbBE549EEacLb6ROZ1C8Fh2AFIgLj3LgJRwWLVSjJcbL29Jcsu-D1IR-YxemWR9o4YH0i7BbJuO30k3pwuK8wJt0Q6TRqvrbE48uESuzzIujs3Ly4T8ClrX1tNNl2DgcPmYbm4X29GI4JBsYvkfCdswt4mr42sI7x7Om-SH1-Xm8XdePX92_1ivhqrPJ-2Y6UrUxrDK2Oo0TyjqQZWFiWDglNdUtCaGzAqZyzLKNNTVZXVjLMiK2cVr3h2k4zOuVtZi33A7Yej8NKKu_lK9DX8ucWMMXpgyA7P7D743x3EVjQ29uuXDnwXBeNFlmZ0ymeIZmdUBR9jAPOczajohRE7cRJG9ML0RRQGuz48DeiqBvRzz8UQBD6fAcCVHCwEERWagTLYAKoV2tv_DPjyT7-qrbNK1r_gCHHnO9SjxpeImAoq1r2zvbK4L8ryPMv-AqQ16p0</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1753230879</pqid></control><display><type>article</type><title>CT imaging findings in patients with advanced hepatocellular carcinoma treated with sorafenib: Alternative response criteria (Choi, European Association for the Study of the Liver, and modified Response Evaluation Criteria in Solid Tumor (mRECIST)) versus RECIST 1.1</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Gavanier, M ; Ayav, A ; Sellal, C ; Orry, X ; Claudon, M ; Bronowicki, J.P ; Laurent, V</creator><creatorcontrib>Gavanier, M ; Ayav, A ; Sellal, C ; Orry, X ; Claudon, M ; Bronowicki, J.P ; Laurent, V</creatorcontrib><description>Highlights • Response or non-response as defined by the Choi criteria exhibited the highest predictive value for overall survival compared with the EASL, RECIST 1.1 and mRECIST criteria. • Patients with progression at the first follow-up examination are never downstaged. • Neither tumor necrosis nor tumor hypervascularization were independent predictors of tumor response.</description><identifier>ISSN: 0720-048X</identifier><identifier>EISSN: 1872-7727</identifier><identifier>DOI: 10.1016/j.ejrad.2015.10.024</identifier><identifier>PMID: 26724654</identifier><language>eng</language><publisher>Ireland: Elsevier B.V</publisher><subject>Adult ; Aged ; Anti-angiogenic therapy ; Antineoplastic Agents - therapeutic use ; Carcinoma, Hepatocellular - diagnostic imaging ; Carcinoma, Hepatocellular - drug therapy ; Carcinoma, Hepatocellular - mortality ; Carcinoma, Hepatocellular - pathology ; Choi ; Female ; Hepatocellular carcinoma ; Humans ; Life Sciences ; Liver - diagnostic imaging ; Liver - pathology ; Liver Neoplasms - diagnostic imaging ; Liver Neoplasms - drug therapy ; Liver Neoplasms - mortality ; Liver Neoplasms - pathology ; Male ; Middle Aged ; mRECIST ; Niacinamide - analogs & derivatives ; Niacinamide - therapeutic use ; Phenylurea Compounds - therapeutic use ; Proportional Hazards Models ; Radiology ; RECIST 1.1 ; Response Evaluation Criteria in Solid Tumors ; Retrospective Studies ; Survival Analysis ; Tomography, X-Ray Computed ; Treatment Outcome ; Tumoral response assessment</subject><ispartof>European journal of radiology, 2016-01, Vol.85 (1), p.103-112</ispartof><rights>Elsevier Ireland Ltd</rights><rights>2015 Elsevier Ireland Ltd</rights><rights>Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c448t-cdbf6ff7bff0fd7302de16561e570d60edd7fefc4113301d8cb6b9715369b7b73</citedby><cites>FETCH-LOGICAL-c448t-cdbf6ff7bff0fd7302de16561e570d60edd7fefc4113301d8cb6b9715369b7b73</cites><orcidid>0000-0002-6715-2979</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0720048X15301443$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,776,780,881,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26724654$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.univ-lorraine.fr/hal-01659110$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Gavanier, M</creatorcontrib><creatorcontrib>Ayav, A</creatorcontrib><creatorcontrib>Sellal, C</creatorcontrib><creatorcontrib>Orry, X</creatorcontrib><creatorcontrib>Claudon, M</creatorcontrib><creatorcontrib>Bronowicki, J.P</creatorcontrib><creatorcontrib>Laurent, V</creatorcontrib><title>CT imaging findings in patients with advanced hepatocellular carcinoma treated with sorafenib: Alternative response criteria (Choi, European Association for the Study of the Liver, and modified Response Evaluation Criteria in Solid Tumor (mRECIST)) versus RECIST 1.1</title><title>European journal of radiology</title><addtitle>Eur J Radiol</addtitle><description>Highlights • Response or non-response as defined by the Choi criteria exhibited the highest predictive value for overall survival compared with the EASL, RECIST 1.1 and mRECIST criteria. • Patients with progression at the first follow-up examination are never downstaged. • Neither tumor necrosis nor tumor hypervascularization were independent predictors of tumor response.</description><subject>Adult</subject><subject>Aged</subject><subject>Anti-angiogenic therapy</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Carcinoma, Hepatocellular - diagnostic imaging</subject><subject>Carcinoma, Hepatocellular - drug therapy</subject><subject>Carcinoma, Hepatocellular - mortality</subject><subject>Carcinoma, Hepatocellular - pathology</subject><subject>Choi</subject><subject>Female</subject><subject>Hepatocellular carcinoma</subject><subject>Humans</subject><subject>Life Sciences</subject><subject>Liver - diagnostic imaging</subject><subject>Liver - pathology</subject><subject>Liver Neoplasms - diagnostic imaging</subject><subject>Liver Neoplasms - drug therapy</subject><subject>Liver Neoplasms - mortality</subject><subject>Liver Neoplasms - pathology</subject><subject>Male</subject><subject>Middle Aged</subject><subject>mRECIST</subject><subject>Niacinamide - analogs & derivatives</subject><subject>Niacinamide - therapeutic use</subject><subject>Phenylurea Compounds - therapeutic use</subject><subject>Proportional Hazards Models</subject><subject>Radiology</subject><subject>RECIST 1.1</subject><subject>Response Evaluation Criteria in Solid Tumors</subject><subject>Retrospective Studies</subject><subject>Survival Analysis</subject><subject>Tomography, X-Ray Computed</subject><subject>Treatment Outcome</subject><subject>Tumoral response assessment</subject><issn>0720-048X</issn><issn>1872-7727</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkl2LEzEUhkdR3O7qLxAkly1sazJfaQWFUqq7UBC2FbwLmeRkmzqT1GSm0n_vmXa7F954FXLmOe8hZ54kec_ohFFWftxNYBeknqSUFViZ0DR_mQzYlKdjzlP-KhlQntIxzac_r5LrGHeU0iKfpW-Sq7TkaV4W-eDF9WJDbCMfrXskxjqNZyTWkb1sLbg2kj-23RKpD9Ip0GQL-MErqOuuloEoGZR1vpGkDSBbBE549EEacLb6ROZ1C8Fh2AFIgLj3LgJRwWLVSjJcbL29Jcsu-D1IR-YxemWR9o4YH0i7BbJuO30k3pwuK8wJt0Q6TRqvrbE48uESuzzIujs3Ly4T8ClrX1tNNl2DgcPmYbm4X29GI4JBsYvkfCdswt4mr42sI7x7Om-SH1-Xm8XdePX92_1ivhqrPJ-2Y6UrUxrDK2Oo0TyjqQZWFiWDglNdUtCaGzAqZyzLKNNTVZXVjLMiK2cVr3h2k4zOuVtZi33A7Yej8NKKu_lK9DX8ucWMMXpgyA7P7D743x3EVjQ29uuXDnwXBeNFlmZ0ymeIZmdUBR9jAPOczajohRE7cRJG9ML0RRQGuz48DeiqBvRzz8UQBD6fAcCVHCwEERWagTLYAKoV2tv_DPjyT7-qrbNK1r_gCHHnO9SjxpeImAoq1r2zvbK4L8ryPMv-AqQ16p0</recordid><startdate>20160101</startdate><enddate>20160101</enddate><creator>Gavanier, M</creator><creator>Ayav, A</creator><creator>Sellal, C</creator><creator>Orry, X</creator><creator>Claudon, M</creator><creator>Bronowicki, J.P</creator><creator>Laurent, V</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>1XC</scope><orcidid>https://orcid.org/0000-0002-6715-2979</orcidid></search><sort><creationdate>20160101</creationdate><title>CT imaging findings in patients with advanced hepatocellular carcinoma treated with sorafenib: Alternative response criteria (Choi, European Association for the Study of the Liver, and modified Response Evaluation Criteria in Solid Tumor (mRECIST)) versus RECIST 1.1</title><author>Gavanier, M ; Ayav, A ; Sellal, C ; Orry, X ; Claudon, M ; Bronowicki, J.P ; Laurent, V</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c448t-cdbf6ff7bff0fd7302de16561e570d60edd7fefc4113301d8cb6b9715369b7b73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Anti-angiogenic therapy</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Carcinoma, Hepatocellular - diagnostic imaging</topic><topic>Carcinoma, Hepatocellular - drug therapy</topic><topic>Carcinoma, Hepatocellular - mortality</topic><topic>Carcinoma, Hepatocellular - pathology</topic><topic>Choi</topic><topic>Female</topic><topic>Hepatocellular carcinoma</topic><topic>Humans</topic><topic>Life Sciences</topic><topic>Liver - diagnostic imaging</topic><topic>Liver - pathology</topic><topic>Liver Neoplasms - diagnostic imaging</topic><topic>Liver Neoplasms - drug therapy</topic><topic>Liver Neoplasms - mortality</topic><topic>Liver Neoplasms - pathology</topic><topic>Male</topic><topic>Middle Aged</topic><topic>mRECIST</topic><topic>Niacinamide - analogs & derivatives</topic><topic>Niacinamide - therapeutic use</topic><topic>Phenylurea Compounds - therapeutic use</topic><topic>Proportional Hazards Models</topic><topic>Radiology</topic><topic>RECIST 1.1</topic><topic>Response Evaluation Criteria in Solid Tumors</topic><topic>Retrospective Studies</topic><topic>Survival Analysis</topic><topic>Tomography, X-Ray Computed</topic><topic>Treatment Outcome</topic><topic>Tumoral response assessment</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gavanier, M</creatorcontrib><creatorcontrib>Ayav, A</creatorcontrib><creatorcontrib>Sellal, C</creatorcontrib><creatorcontrib>Orry, X</creatorcontrib><creatorcontrib>Claudon, M</creatorcontrib><creatorcontrib>Bronowicki, J.P</creatorcontrib><creatorcontrib>Laurent, V</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><jtitle>European journal of radiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gavanier, M</au><au>Ayav, A</au><au>Sellal, C</au><au>Orry, X</au><au>Claudon, M</au><au>Bronowicki, J.P</au><au>Laurent, V</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>CT imaging findings in patients with advanced hepatocellular carcinoma treated with sorafenib: Alternative response criteria (Choi, European Association for the Study of the Liver, and modified Response Evaluation Criteria in Solid Tumor (mRECIST)) versus RECIST 1.1</atitle><jtitle>European journal of radiology</jtitle><addtitle>Eur J Radiol</addtitle><date>2016-01-01</date><risdate>2016</risdate><volume>85</volume><issue>1</issue><spage>103</spage><epage>112</epage><pages>103-112</pages><issn>0720-048X</issn><eissn>1872-7727</eissn><abstract>Highlights • Response or non-response as defined by the Choi criteria exhibited the highest predictive value for overall survival compared with the EASL, RECIST 1.1 and mRECIST criteria. • Patients with progression at the first follow-up examination are never downstaged. • Neither tumor necrosis nor tumor hypervascularization were independent predictors of tumor response.</abstract><cop>Ireland</cop><pub>Elsevier B.V</pub><pmid>26724654</pmid><doi>10.1016/j.ejrad.2015.10.024</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0002-6715-2979</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0720-048X |
| ispartof | European journal of radiology, 2016-01, Vol.85 (1), p.103-112 |
| issn | 0720-048X 1872-7727 |
| language | eng |
| recordid | cdi_hal_primary_oai_HAL_hal_01659110v1 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Adult Aged Anti-angiogenic therapy Antineoplastic Agents - therapeutic use Carcinoma, Hepatocellular - diagnostic imaging Carcinoma, Hepatocellular - drug therapy Carcinoma, Hepatocellular - mortality Carcinoma, Hepatocellular - pathology Choi Female Hepatocellular carcinoma Humans Life Sciences Liver - diagnostic imaging Liver - pathology Liver Neoplasms - diagnostic imaging Liver Neoplasms - drug therapy Liver Neoplasms - mortality Liver Neoplasms - pathology Male Middle Aged mRECIST Niacinamide - analogs & derivatives Niacinamide - therapeutic use Phenylurea Compounds - therapeutic use Proportional Hazards Models Radiology RECIST 1.1 Response Evaluation Criteria in Solid Tumors Retrospective Studies Survival Analysis Tomography, X-Ray Computed Treatment Outcome Tumoral response assessment |
| title | CT imaging findings in patients with advanced hepatocellular carcinoma treated with sorafenib: Alternative response criteria (Choi, European Association for the Study of the Liver, and modified Response Evaluation Criteria in Solid Tumor (mRECIST)) versus RECIST 1.1 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T21%3A10%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=CT%20imaging%20findings%20in%20patients%20with%20advanced%20hepatocellular%20carcinoma%20treated%20with%20sorafenib:%20Alternative%20response%20criteria%20(Choi,%20European%20Association%20for%20the%20Study%20of%20the%20Liver,%20and%20modified%20Response%20Evaluation%20Criteria%20in%20Solid%20Tumor%20(mRECIST))%20versus%20RECIST%201.1&rft.jtitle=European%20journal%20of%20radiology&rft.au=Gavanier,%20M&rft.date=2016-01-01&rft.volume=85&rft.issue=1&rft.spage=103&rft.epage=112&rft.pages=103-112&rft.issn=0720-048X&rft.eissn=1872-7727&rft_id=info:doi/10.1016/j.ejrad.2015.10.024&rft_dat=%3Cproquest_hal_p%3E1753230879%3C/proquest_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1753230879&rft_id=info:pmid/26724654&rft_els_id=1_s2_0_S0720048X15301443&rfr_iscdi=true |